Myonectin serum concentration changes after short-term physical activity among young, healthy people

ABSTRACT
Background: Myonectin is a myokine secreted by skeletal muscles in response to physical activity (PhA) in rodents. It was shown that myonectin may be positively associated with insulin resistance parameters. The aim of the study was to evaluate changes in the concentration of myonectin after short-term PhA.

Methods: A total of 29 young, healthy volunteers, were included in the study. Each participant completed a lifestyle questionnaire, underwent a physical examination with anthropometric measurement followed by a treadmill test according to the Bruce protocol. Blood samples were collected before and after PhA. An ELISA Assay was used to investigate the myonectin serum level.

Results: The myonectin serum level did not change significantly after PhA (0.62[0.14-2.9] vs. 1.08[0.15-2.44] ng/ml; p=0.84). Before PhA the myonectin serum level differed significantly between men and women (respectively: 3.92[2.24-5.30] vs. 0.56[0.15-1.75] ng/ml; p=0.02). Before PhA it had a positive association with weight, BMI, serum creatinine and uremic acid (p < 0.05). The change in the level of myonectin serum after PhA had negative associations with weight, BMI, fasting insulin level and HOMA-IR (p < 0.05).

Conclusions: Myonectin serum concentration does not change after short-term physical activity among young, healthy people. Changes in the myonectin serum level after short-term physical activity may be associated with fasting insulin resistance.

Keywords: myonectin, physical, activity, insulin, resistance, treadmill, homa-ir

Introduction

Myonectin (CTRP15/C1QTNF/erythroferrone) is a novel myokine secreted by skeletal muscles in response to physical activity (PhA) and the rise of glucose and free fatty acids (FFA) in rodents [1–2]. Myonectin increases the expression of proteins transporting FFA through hepatocytes and adipocyte cell membranes, causing increasing serum FFA uptake [3]. Toloza et al. reported that myonectin level is associated with insulin resistance (IR) in non-diabetic adults [4]. Lim et al. observed that long-term, regular PhA decreases both the myonectin serum level and IR measured by the homeostasis model assessment [5].

It is known that short-term PhA transiently increases serum levels of glucose, FFA and IR [6]. In this context, it may be suspected that myonectin serum level should increase after short-term PhA in humans. Currently, no study has yet investigated changes in myonectin serum level after short-term PhA in human adults.

The aim of the study was to evaluate changes in the concentration of myonectin after short-term physical activity.

Materials and Methods

Design

Cross-sectional, single-centre study.

Data Collection

The study group consisted of volunteers, young healthy people. All patients were informed about the study and signed an informed consent form. The study
protocol was approved by the local Ethic Committee (Bioethics Committee of Poznan University of Medical Sciences).

Inclusion and exclusion criteria

All patients who met the following criteria were included: age between 18–26, visit worklab in fasting state, voluntarily signed a consent form. Exclusion criteria were as follows: metabolic syndrome, acute infection, mental disorder, congenital disease, unstable chronic disease, general exclusion criteria for a treadmill test.

Clinical and laboratory data

The worklab visit took place in the morning hours (8:00–10:00 AM). All participants had been informed not to eat, drink or smoke 8 hours prior to attendance. All individuals completed a questionnaire including details of sex, age, smoking status and The International Physical Activity Questionnaire (IPAQ) — a validated questionnaire used to assess weekly PhA expressed as a total weekly metabolic equivalent of the task (MET) [7]. The patients underwent a complete physical examination with anthropometric measurements (weight, height, waist circumference) and blood pressure check. Blood pressure was measured three times by the Korotkoff method in the sitting position, after 10 minutes rest, using a mercury manometer. Blood pressure was additionally measured after 6 minutes of treadmill test. Height and weight were measured using the same medical scales for all patients. Weight was measured to an accuracy of 100 g and height to 0.5 cm. BMI was calculated from the following equations: BMI = weight / squared height [kg/m2].

Blood samples were collected in a fasting state using the S-Monovette blood collection system. Serum glucose, serum insulin, creatinine, uremic acid and lipid profile were assessed according to standard laboratory protocols. After the first blood sample collection and before the treadmill test, participants ate breakfast. 6 minutes after the treadmill test a second blood sample was obtained to assess myonectin serum level after PhA. To estimate myonectin serum concentration Human (CTRP15/Myonectin) ELISA Kit (ElAab, China) was used. All steps of the assay were done according to the manufacturer’s instructions. Changes in the myonectin serum level were defined as the difference to the manufacturer’s instructions. Moreover, serum creatinine and uremic acid levels are dependent on muscle mass [10–11]. These associations may provide a rationale for the observed results.

Discussion

In this study, no significant change was observed in the myonectin serum level after short-term PhA. Myonectin before PhA was also associated with weight, BMI, serum creatinine and uremic acid. The groups of men and women differed significantly in age, height, weight, BMI, HDL-C, serum creatinine, uremic acid and myonectin before PhA levels. Myonectin is secreted by skeletal muscles. Skeletal muscle mass in young, healthy adults is positively correlated with weight, BMI. Myonectin in response to PhA increases the expression of CD36, fatty acid transport proteins (FATP), and fatty acid binding proteins (FABP) in hepatocytes and adipocyte, resulting in increasing FFA uptake [2]. It is known that myonectin is associated with IR [4–5] and circulating FFA induces IR [12]. It is possible that myonectin is secondarily upregulated in the IR state in order to diminish circulating FFA levels. In a young,

Statistical analysis

Statistical analysis was performed with STATISTICA 12.0 (StatSoft, USA). The normality of variable distributions was tested using the Shapiro-Wilk test. For descriptive analysis, Wilcoxon test was used to compare the results before and after the treadmill test; the Mann-Whitney was performed to compare men and women. For comparison of binary variables, Fisher’s exact test was used. Differences with a p-value < 0.05 were considered statistically significant.

Results

The study group consisted of 29 participants (male = 10; 34.5%), the features of the group are presented in Table 1. All participants had myonectin serum levels within the assay range (0.05–15 ng/ml). To compare myonectin serum levels and other features between men and women the Mann-Whitney U test and Fisher’s exact test were used.

Differences between myonectin serum level, heart rate, systolic and diastolic blood pressure before and after physical activity were presented in Table 2. The R Spearman rank correlation test revealed some significant associations between myonectin serum level (Table 3).
Table 1. General characteristics of the study group

| Feature [units] | Median (IQR) / n (%) | Female (n = 19) | Male (n = 10) | p-value |
|-----------------|----------------------|-----------------|--------------|---------|
| Smokers         | 4 (13.8)             | 2 (10.5)        | 2 (20.0)     | 0.43    |
| Age [years]     | 22 (20–23)           | 21 (20–22)      | 23 (22–23)   | < 0.01  |
| Height [m]      | 1.72 (16.5–1.76)     | 1.69 (1.64–1.72)| 1.82 (1.76–1.85) | < 0.001 |
| Weight [kg]     | 59 (54–78)           | 54 (53–59)      | 80 (78–86)   | < 0.001 |
| BMI [kg/m²]     | 21.3 (19.4–24.0)     | 20.1 (18.5–21.3)| 24.0 (23.8–25.7) | < 0.001 |
| Fasting Glucose [mmol/l]| 5.1 (4.8–5.3)       | 5.1 (4.8–5.3)   | 5.1 (4.6–5.4) | 0.80    |
| Fasting insulin [μIU/ml]| 16.1 (12.5–19.1)    | 16.7 (12.1–18.6)| 15.2 (12.8–19.6) | 0.79    |
| HOMA-IR         | 3.7 (2.8–4.3)        | 3.7 (2.6–4.2)   | 3.4 (3.0–4.3) | 0.98    |
| Total Cholesterol [mmol/l]| 4.4 (3.9–5.2)       | 4.4 (4.2–5.4)   | 4.0 (3.7–4.6) | 0.07    |
| HDL-C [mmol/l]  | 1.6 (1.4–1.9)        | 1.7 (1.5–2.1)   | 1.4 (1.2–1.7) | 0.04    |
| LDL-C [mmol/l]  | 2.3 (2.0–3.0)        | 2.3 (2.0–3.1)   | 2.2 (1.8–2.5) | 0.35    |
| Triglycerides [mmol/l]| 0.84 (0.61–1.1)     | 0.85 (0.63–1.1) | 0.70 (0.48–0.98) | 0.33    |
| Serum Creatinine [μmol/l]| 70.4 (70.3–79.6)    | 70.7 (61.9–70.7)| 88.4 (79.6–97.3) | < 0.001 |
| Uremic Acid [μmol/l]| 279.6 (243.9–339.0) | 243.9 (214.1–279.6) | 358.9 (339.0–395.5) | < 0.001 |
| METmax during Treadmill Test [kcal/kg/h]| 11.8 (10.4–14.3) | 11.5 (10.4–14.0) | 13.9 (11.8–14.8) | 0.23    |
| IPAQ Total Weekly MET [kcal/kg/h]| 3448 (1794–4730)   | 3842 (1794–5205) | 2669 (1328–3900) | 0.11    |
| Myonectin before PhA [ng/ml]| 0.67 (0.14–2.9)    | 0.15 (0.14–1.09) | 3.92 (2.24–5.30) | 0.02    |
| Myonectin after PhA [ng/ml]| 1.08 (0.15–2.44)   | 0.56 (0.15–1.75) | 2.43 (0.78–4.00) | 0.09    |
| Change of the Myonectin Serum Level | 0.01 (–0.84 – 0.67) | 0.01 (–0.17 – 0.95) | – 0.65 (–3.38 – 0.67) | 0.10    |

BMI — Body Mass Index, HDL-C — High-Density Lipoprotein Cholesterol, HOMA-IR — Homeostatic Model Assessment Measuring Insulin Resistance, IPAQ — The International Physical Activity Questionnaire, IQR — Interquartile Range, LDL — Low-Density Lipoprotein Cholesterol, MET — Metabolic Equivalent of Task, METmax — Maximal MET

Table 2. Wilcoxon test outcomes

|                      | Before Physical Activity median (IQR) | After Physical Activity median (IQR) | p value |
|----------------------|--------------------------------------|--------------------------------------|---------|
| Myonectin [ng/ml]    | 0.67 (0.14–2.9)                      | 1.08 (0.15–2.44)                     | 0.84    |
| Systolic Blood Pressure [mmHg] | 115 (110–124)                    | 120 (112–124)                        | 0.20    |
| Diastolic Blood Pressure [mmHg]  | 75 (70–80)                          | 72 (70–80)                           | 0.28    |
| Heart Rate [bpm]     | 82 (78–93)                           | 96 (91–100)                          | < 0.001 |

Healthy population with no presence of metabolic syndrome, the release of myonectin might be too low and/or slow in comparison with patients with IR to observe any significant change in myonectin serum level in 6 minutes after short-term PhA.

Interestingly, the change in the myonectin serum level after short-term PhA was negatively associated with both insulin in fasting state and HOMA-IR. Toloza et al. studied 81 non-diabetic adults and assessed the association between insulin resistance direct and indirect markers and myokines [4]. Fasting myonectin adjusted to BMI, age and sex were found to be negatively associated with the Insulin Sensitivity Index (standardized beta = -0.235, p = 0.023). The authors did not report any significant association with HOMA-IR. Lim et al. investigated the effects of 1-h per week of aerobic physical activity lasting 10-weeks on myonectin and insulin resistance in 14 young (22.5 ± 2.7 years) and 14 older (60.3 ± 5.2 years) women [5]. Before the training a positive correlation between HOMA-IR and myonectin serum level was found only in older women in fasting state at rest (r = 0.35; p < 0.05). After 10-weeks of training, changes in HOMA-IR and changes in myonectin were positively correlated (r = 0.462; p < 0.01) in both groups. Both the aforementioned studies demonstrated a positive dependence between insulin resistance and...
### Table 3. Associations between study features and myonectin serum level

| Feature [units] | Myonectin Before Physical Activity [ng/ml] | Myonectin After Physical Activity [ng/ml] | Change of the Myonectin Serum Level [ng/ml] |
|-----------------|-------------------------------------------|------------------------------------------|---------------------------------------------|
| Age [years]     | 0.33 0.08                                | 0.24 0.22                                | -0.14 0.47                                  |
| Height [m]      | 0.30 0.11                                | 0.35 0.07                                | -0.08 0.68                                  |
| Weight [kg]     | **0.38** 0.04                           | **0.21** 0.29                           | **-0.41** 0.03                              |
| BMI [kg/m²]     | **0.40** 0.03                           | **0.19** 0.31                           | **-0.47** 0.01                              |
| Fasting Glucose [mmol/] | 0.07 0.71 | 0.13 0.50 | -0.03 0.88 |
| Fasting insulin [μIU/ml] | 0.09 0.64 | -0.25 0.19 | **-0.38** 0.04 |
| HOMA-IR         | 0.15 0.45                                | -0.21 0.29                               | **-0.43** 0.02                              |
| Total Cholesterol [mmol/l] | -0.01 0.95 | 0.19 0.32 | 0.20 0.30 |
| HDL-C [mmol/l]  | -0.21 0.28                               | 0.04 0.84                                | 0.21 0.28                                  |
| LDL-C [mmol/l]  | 0.13 0.49                                | 0.30 0.11                                | 0.15 0.44                                  |
| Triglycerides [mmol/] | -0.12 0.55 | -0.35 0.06 | -0.23 0.22 |
| Serum Creatinine [μmol/l] | 0.40 0.03 | 0.32 0.09 | -0.32 0.09 |
| Uremic Acid [μmol/l] | 0.41 0.03 | 0.43 0.02 | -0.17 0.38 |
| METmax during Treadmill Test [kcal/kg/h] | 0.16 0.41 | 0.04 0.84 | -0.20 0.30 |
| IPAQ Total Weekly MET [kcal/kg/h] | -0.06 0.78 | -0.07 0.71 | 0.01 0.10 |

**BMI** — Body Mass Index, **HDL-C** — High-Density Lipoprotein Cholesterol, **HOMA-IR** — Homeostatic Model Assessment Measuring Insulin Resistance, **IPAQ** — The International Physical Activity Questionnaire, **IQR** — Interquartile Range, **LDL** — Low-Density Lipoprotein Cholesterol, **MET** — Metabolic Equivalent of Task, **METmax** — Maximal MET

Myonectin. In our study, no such association was found. However, the negative association between changes in the myonectin serum level after PhA and simultaneously no significant change in myonectin serum level after PhA is intriguing. The change in myonectin serum level is highest among young volunteers with the lowest HOMA-IR value in the fasting state. It is possible that in those groups an increase of myonectin is more rapid than in the group characterized by higher HOMA-IR values. However, this possible phenomenon requires more detailed studies.

This study has several limitations. Firstly, we included only 29 volunteers in the study. Secondly, no additional data such as body composition or FFA were collected. Body composition analysis may reveal a potential association between myonectin serum level and muscle mass. Finally, we have not collected blood samples after a longer period of time than 6 minutes.

In conclusion, myonectin serum concentration does not change after short-term physical activity among young, healthy people. Myonectin serum level may be associated with muscle mass in a young, healthy population. Changes in myonectin serum level after short-term physical activity may be associated with fasting insulin resistance.

### Disclosure

None of the authors declared any potential conflict of interests.

### Funding

This work was supported by a Student’s grant of the Student Scientific Society, Poznan University of Medical Sciences.[140/2016]

**Contribution:**
- Concept — CM, KarM
- Data collection — KamM, JK, GA, SJ
- KarM, CM
- Laboratory analysis — LB, WA
- Statistical analysis — KamM, Draft preparation — KamM, Final approval — KamM, JK, GA, SJ, KarM, LB, WA, CM

### List of abbreviations:

- FFA — Free Fatty Acids
- IPAQ — The International Physical Activity Questionnaire
- IR — Insulin Resistance
- MET — Metabolic Equivalent of the Task
- PhA — Physical Activity
References

1. Park SY, Choi JH, Ryu HSu, et al. C1q tumor necrosis factor alpha-related protein isoform 5 is increased in mitochondrial DNA-depleted myocytes and activates AMP-activated protein kinase. J Biol Chem. 2009; 284(41): 27780–27788. doi: 10.1074/jbc.M109.005611, indexed in Pubmed: 19651784.

2. Seldin MM, Peterson JM, Byerly MS, et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287(15): 11968–11980. doi: 10.1074/jbc.M111.336834, indexed in Pubmed: 22351773.

3. Sharma N, Castorena CM, Cartee GD. Greater insulin sensitivity in calorie restricted rats occurs with unaltered circulating levels of several important myokines and cytokines. Nutr Metab (Lond). 2012; 9(1): 90. doi: 10.1186/1743-7075-9-90, indexed in Pubmed: 23067400.

4. Toloza FJK, Mantilla-Rivas JO, Pérez-Matos MC, et al. Plasma Levels of Myonectin But Not Myostatin or Fibroblast-Derived Growth Factor 21 Are Associated with Insulin Resistance in Adult Humans without Diabetes Mellitus. Front Endocrinol (Lausanne). 2018; 9: 5. doi: 10.3389/fendo.2018.00005, indexed in Pubmed: 29445355.

5. Lim S, Choi SH, Koo BoK, et al. Effects of aerobic exercise training on C1q tumor necrosis factor α-related protein isoform 5 (myonectin): association with insulin resistance and mitochondrial DNA density in women. J Clin Endocrinol Metab. 2012; 97(1): E88–E93. doi: 10.1210/jc.2011-1743, indexed in Pubmed: 22031510.

6. Kövist V, Yki-Järvinen H, DeFronzo R. Physical training and insulin sensitivity. Diabetes / Metabolism Reviews. 1986; 1(4): 445–481. doi: 10.1002/dmr.5610010407.

7. Hagströmer M, Oja P. Sjöström M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006; 9(6): 755–762, indexed in Pubmed: 16925881.

8. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419, indexed in Pubmed: 3899625.

9. Bruce R. Methods of exercise testing. The American Journal of Cardiology. 1974; 33(6): 715–720. doi: 10.1016/0002-9149(74)90211-2.

10. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008; 3(2): 348–354. doi: 10.2215/CJN.02870707, indexed in Pubmed: 18235143.

11. Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8–14. doi: 10.1016/j.ijcard.2015.08.109, indexed in Pubmed: 26316329.

12. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol. 2012; 57(2-4): 91–97. doi: 10.1016/j.vph.2012.05.003, indexed in Pubmed: 22659131.